Perseris (Risperidone Extended-Release Injectable Suspension)

What is Perseris?

Perseris represents a significant advancement in long-acting injectable (LAI) antipsychotic therapy, offering once-monthly administration through subcutaneous delivery. This formulation provides sustained therapeutic plasma concentrations of risperidone, the active metabolite, eliminating the need for daily oral medication adherence while maintaining efficacy in schizophrenia management.

Pharmacological Classification

Perseris Active Ingredient and Composition

Active Pharmaceutical Ingredient:

• Risperidone: 90 mg, 120 mg, or 180 mg per prefilled syringe (equivalent to risperidone base)

Formulation Technology: Perseris utilizes proprietary ATRIGEL® delivery system, a biodegradable polymer matrix consisting of:

• Poly(DL-lactide-co-glycolide) (PLGA) copolymer
• N-methyl-2-pyrrolidone (NMP) solvent
• Risperidone drug substance

Upon subcutaneous injection, the NMP diffuses into surrounding tissue, causing the PLGA to precipitate and form a solid depot. This depot slowly biodegrades through hydrolysis, releasing risperidone at controlled rates over approximately 30 days.

Perseris Mechanism of Action

Risperidone demonstrates high affinity antagonism at multiple neurotransmitter receptors:

The 5-HT₂A/D₂ affinity ratio (>15:1) characterizes risperidone as an atypical antipsychotic, providing efficacy against positive symptoms with reduced extrapyramidal symptom burden compared to first-generation agents.

Indications and Approved Uses

Primary Indication: Treatment of schizophrenia in adults

Specific Applications:

• Maintenance treatment following acute stabilization
• Prevention of relapse in chronic schizophrenia
• Management of patients with adherence challenges to oral antipsychotics
• Long-term symptom control and functional recovery

Off-Label Considerations (not FDA-approved but clinically utilized):

• Bipolar I disorder maintenance (based on oral risperidone data)
• Treatment-resistant depression augmentation
• Behavioral disturbances in dementia (with caution)
• Autism-associated irritability (pediatric oral formulation only)

Perseris Dosage and Administration

Available Dosage Strengths

Dosing Guidelines

Initial Dosing:

• 90 mg once monthly for patients not previously stabilized on oral risperidone
• 90 mg once monthly for patients stabilized on oral risperidone ≤4 mg/day
• 120 mg once monthly for patients stabilized on oral risperidone 5-6 mg/day

Maintenance Dosing:

• Adjust dose based on clinical response and tolerability
• Range: 90 mg to 180 mg monthly
• Minimum interval between injections: 23 days

Switching from Oral Risperidone:

• Administer Perseris and last oral dose concurrently
• Therapeutic plasma concentrations achieved within 4-6 hours of injection
• Discontinue oral risperidone after first injection

Missed Dose Management:

Administration Technique

Injection Site: Abdominal subcutaneous tissue (avoid 2-inch radius around navel)

Procedure:

1. Allow syringe to reach room temperature (30 minutes)
2. Inspect for particulate matter or discoloration
3. Do not shake—gentle swirling if needed
4. Pinch abdominal skin fold
5. Insert needle at 45-90° angle
6. Inject entire contents over 5-10 seconds
7. Apply gentle pressure; do not rub
8. Rotate injection sites monthly

Storage Requirements:

• Refrigerate at 2-8°C (36-46°F)
• Protect from light
• Room temperature stability: 24 hours maximum

Perseris Pharmacokinetics

Absorption and Distribution

Metabolism and Elimination

Metabolic Pathway:

• Primary: CYP2D6 hydroxylation → 9-hydroxyrisperidone (paliperidone)
• Secondary: CYP3A4 oxidation
• 9-hydroxyrisperidone possesses equivalent pharmacological activity

Excretion:

• Urine: 70% (35% as unchanged drug and metabolites)
• Feces: 14%
• Clearance reduced in hepatic and renal impairment

Steady-State Characteristics

• Steady-state achieved after 3-4 monthly injections
• Peak-to-trough fluctuation: ~40-50%
• No significant accumulation beyond expected steady-state levels

Clinical Efficacy Data

Pivotal Clinical Trials

Study 1: Relapse Prevention (NCT01631573)

• Design: Randomized, double-blind, placebo-controlled
• Duration: 12 months
• Population: Adults with schizophrenia, clinically stable
• Results:
  • Relapse rate: Perseris 12.5% vs. Placebo 38.5%
  • Hazard ratio: 0.28 (95% CI: 0.18-0.44)
  • Number needed to treat (NNT): 3.8

Study 2: Acute Efficacy (NCT01435734)

• Design: Randomized, active-controlled (oral risperidone)
• Duration: 8 weeks
• Primary endpoint: PANSS total score change
• Results: Non-inferior to oral risperidone (mean difference -2.1, 95% CI: -6.3 to 2.1)

Long-Term Effectiveness

Safety Profile and Adverse Reactions

Common Adverse Events (≥5% and >2× placebo)

Serious Adverse Reactions

Boxed Warnings:

1. Increased Mortality in Elderly Patients with Dementia-Related Psychosis
   • Risk of death 1.6-1.7× vs. placebo
   • Perseris not approved for dementia-related psychosis
2. Suicidal Thoughts and Behaviors
   • Monitor all patients for emergence or worsening of suicidality

Other Critical Safety Concerns:

Perseris Injection Site Reactions

Characteristics:

• Typically mild to moderate severity
• Onset: Within 24-48 hours
• Duration: 3-7 days (majority resolve spontaneously)
• Incidence decreases with subsequent injections

Management:

• Cold compresses for first 24 hours
• Warm compresses after 48 hours if persistent
• Topical corticosteroids for severe reactions
• Consider alternative site or oral therapy if recurrent severe reactions

Perseris Contraindications and Precautions

Absolute Contraindications

• Known hypersensitivity to risperidone, paliperidone, or formulation components
• Severe hepatic impairment (Child-Pugh Class C)
• Pre-existing severe neutropenia or history of drug-induced agranulocytosis

Warnings and Precautions

Drug Interactions

Pharmacokinetic Interactions

Pharmacodynamic Interactions

Special Populations

Geriatric Patients (≥65 years)

• No specific dose adjustment required
• Increased sensitivity to orthostatic hypotension and sedation
• Enhanced monitoring for metabolic effects
• Black box warning: Contraindicated for dementia-related psychosis

Hepatic Impairment

Renal Impairment

Pregnancy and Lactation

Pregnancy Category: C

• Risk of EPS and withdrawal symptoms in neonates (third trimester exposure)
• Risk of gestational diabetes
• Limited human data; animal studies show teratogenicity at high doses

Lactation:

• Excreted in breast milk
• Recommendation: Discontinue nursing or drug

Monitoring Parameters

Baseline Assessment

• Complete blood count with differential
• Comprehensive metabolic panel (glucose, lipids)
• Prolactin level
• Weight and waist circumference
• Vital signs (orthostatic blood pressure)
• ECG (if cardiac risk factors)
• Pregnancy test (women of childbearing potential)

Ongoing Monitoring

Comparison with Other Long-Acting Injectable Antipsychotics

Patient Counseling Information

Key Educational Points

Medication Adherence:

• Importance of monthly appointments
• Consequences of missed doses (relapse risk)
• Planning for travel or relocation

Injection Experience:

• Temporary lump at injection site (normal)
• Rotation of abdominal sites
• Report severe or persistent reactions

Emergency Situations:

Regulatory Status and Availability

Clinical Pearls and Practical Considerations

Advantages of Perseris

1. Subcutaneous administration reduces patient anxiety vs. intramuscular injections
2. No oral overlap required simplifies initiation
3. Rapid achievement of therapeutic levels
4. Predictable pharmacokinetics with monthly intervals
5. Patient self-administration potential (with appropriate training)

Clinical Challenges

1. Injection site reactions may limit tolerability in sensitive individuals
2. Fixed dosing intervals less flexible than oral therapy
3. Refrigeration requirements complicate distribution
4. Cost considerations compared to generic oral risperidone

Optimal Patient Selection

• History of non-adherence with oral antipsychotics
• Preference for less frequent dosing
• Stable on oral risperidone seeking convenience
• Ability to attend monthly appointments
• Adequate abdominal subcutaneous tissue

Further Reading

1. FDA Prescribing Information for Perseris (risperidone) extended-release injectable suspension. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210655s010lbl.pdf

Sources & References

1. U.S. Food and Drug Administration (2018) Perseris (risperidone) extended-release injectable suspension for subcutaneous use: NDA 210655 approval package. Silver Spring, MD: FDA.
2. Indivior Inc. (2023) PERSERIS (risperidone) extended-release injectable suspension, for subcutaneous use: Prescribing information. Richmond, VA: Indivior Inc.
3. Correll, C.U. et al. (2019) ‘Efficacy and safety of a once-monthly subcutaneous extended-release risperidone injection for the treatment of schizophrenia: results from a phase 3, randomized, double‑blind, placebo‑controlled trial’, Journal of Clinical Psychopharmacology, 39(5), pp. 428–436.
4. Weiden, P.J. and Preskorn, S.H. (2015) ‘Long-acting injectable antipsychotics: guidelines for effective use’, Journal of Psychiatric Practice, 21(4), pp. 302–312.
5. Kane, J.M. et al. (2013) ‘Long-acting injectable antipsychotics: a systematic review and meta-analysis of randomized controlled trials’, Journal of Clinical Psychiatry, 74(10), pp. 957–965.
6. Risperdal (risperidone) [package insert] (latest version). Titusville, NJ: Janssen Pharmaceuticals.
7. Marder, S.R. (1999) ‘A review of risperidone in the treatment of patients with schizophrenia’, International Clinical Psychopharmacology, 14(Suppl 2), pp. S15–S18.
8. Leucht, S. et al. (2013) ‘Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple‑treatments meta‑analysis’, The Lancet, 382(9896), pp. 951–962.
9. Citrome, L. (2017) ‘Long-acting injectable antipsychotics: what do we know, and where do we go?’, CNS Drugs, 31(9), pp. 829–847.
10. Correll, C.U. and Schooler, N.R. (2020) ‘Long-acting injectable antipsychotics for schizophrenia: from clinical research to clinical practice’, American Journal of Psychiatry, 177(10), pp. 923–936.
11. Nasrallah, H.A. (2007) ‘The case for long-acting antipsychotic agents in the post-CATIE era’, Acta Psychiatrica Scandinavica, 115(4), pp. 260–267.
12. Haddad, P.M., Haddad, P., Taylor, M. and Niaz, O. (2009) ‘Antipsychotic long-acting injections: adherence, safety and patient preference’, Patient Preference and Adherence, 3, pp. 345–355.
13. Remington, G. et al. (2011) ‘Guidelines for the pharmacotherapy of schizophrenia in adults’, Canadian Journal of Psychiatry, 56(9), pp. 549–562.
14. Keepers, G.A. et al. (2020) ‘The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia’, American Journal of Psychiatry, 177(9), pp. 868–872.
15. Citrome, L. (2013) ‘New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia’, Expert Review of Neurotherapeutics, 13(7), pp. 767–783.
16. Jibson, M.D. (2020) ‘Second-generation antipsychotic medications: pharmacology, administration, and side effects’, UpToDate [clinical review].
17. Peuskens, J. and Pani, L. (2014) ‘Risperidone in the treatment of schizophrenia: an update’, Neuropsychiatric Disease and Treatment, 10, pp. 109–123.
18. De Hert, M. et al. (2011) ‘Metabolic and cardiovascular adverse effects associated with antipsychotic drugs’, Nature Reviews Endocrinology, 7(3), pp. 114–126.
19. Haddad, P.M. and Correll, C.U. (2018) ‘The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses’, Therapeutic Advances in Psychopharmacology, 8(11), pp. 303–318.
20. Bushe, C. and Shaw, M. (2007) ‘Prevalence of hyperprolactinaemia in schizophrenia: association with typical and atypical antipsychotic treatment’, Journal of Psychopharmacology, 21(8), pp. 768–773.